Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk - Test2 - elhamkhani - TriplyDB

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

http://www.wikidata.org/entity/Q28168742

about

Do early premalignant changes in normal breast epithelial cells predict cancer development?Aspirin and breast cancer prevention--a link to ER status Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer Obesity and cancer: mechanistic insights from transdisciplinary studies Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers Use of acetaminophen in relation to the occurrence of cancer: a review of epidemiologic studies COX inhibitors and breast cancer Association of regular aspirin use and breast cancer risk Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer NSAIDs and breast cancer recurrence in a prospective cohort study Cyclooxygenase-2 and the inflammogenesis of breast cancer.Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin The case for developing publicly-accessible datasets for health services research in the Middle East and North Africa (MENA) region Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study.The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer.Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.Analgesic use and sex steroid hormone concentrations in postmenopausal women.Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women.Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women.Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study.Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial.Low-dose aspirin in the primary prevention of rheumatoid arthritis: the Women's Health Study.Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.Preventative therapies for healthy women at high risk of breast cancer.Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis.Urinary prostaglandin E2 metabolite and breast cancer risk.Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation.Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study.Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer.HMG CoA reductase inhibitors, NSAIDs and risk of glioma

P2860

Q24796939-E156B05A-FC7D-4D94-A8E0-40149011482F Q24806520-6F9F3A3E-1891-4938-8663-7CCDE3969C64 Q25257496-3DDBED69-7309-4F82-BFC3-5B0A94A65E89 Q26786829-60DFC77D-1243-4A55-9858-A222D7BE62C9 Q27016106-D0D9A2F6-8DCB-41C7-B501-24E909C5B005 Q28075857-EE92202B-AC42-4455-8B09-F380CD6812B0 Q28194592-D59EBDCB-248C-4AFD-B53E-940276B7F4B4 Q28211831-8AF9E176-E921-43B2-9F09-DA308727F964 Q28213217-05128128-F5E3-47F2-8CE8-25390871CD94 Q28218639-3934CD2F-502C-48B6-BD51-168F3E9FD35D Q28221965-3D87293A-B411-480A-9F3E-170FD324F637 Q30367680-3CCDD782-0383-44AA-BE8D-96D9EB6C4A78 Q30523992-FBD63FEB-F9CC-469C-92DC-F722B1F4C175 Q33513734-FFF3D4B3-68F2-4D3F-BFFA-ED56DB36046E Q33566322-C683BCFC-3F5B-4FD0-9802-C44635685275 Q33619700-D53CB838-1E9F-4D41-8930-3136BB0BB0DE Q33664316-712BC48C-9A88-4AD3-A26F-3CB231B366CC Q33739341-678E06EF-739E-449C-A458-2892B632CA60 Q33780860-086B0F88-8A99-4181-A0CF-3937B3A63EE2 Q33811534-D5980155-482C-4DE2-9F7C-C24F7D045ACA Q33889458-F36C7108-8089-400E-AD98-E715109D54C7 Q34034263-BD1F3439-2342-4A64-BB8F-2733623A2D39 Q34069337-8D89AA89-5485-4D38-93C3-1F38871735A7 Q34135505-6728C4AF-2465-4DB3-82D4-B342D37F980D Q34343159-85C5A389-6F30-4A83-A04F-6B67B21A9E65 Q34381496-989F7149-552B-4D5A-B98A-67A6191F7887 Q34393592-C6D4903E-90A8-4BE1-87D0-529CB4C30CC4 Q34458235-A50163F8-E6D2-47A8-8F7C-F43BFBB4CC69 Q34641787-B19833F6-887C-4778-BD8E-272753689D4B Q35048404-2A9E4B98-18F9-4D3E-ABF6-CDB2B7DA06BF Q35227086-92F32D05-84B0-4BEC-9239-7D13974BD8CC Q35426181-CA368CA8-CD69-4532-B512-14D225548EF3 Q35554865-F03BD8F4-A9FE-416B-AD9A-9030557020B3 Q35595696-30B7F0DF-DED2-4B00-834F-C37BC21B4E5F Q35648998-5363F4F8-083C-4FD2-830C-5C3B1A903C4E Q35711979-3DC748C0-424B-491E-A9F0-6FE653E0CAEF Q35770111-86A4F531-E09E-47E7-BA31-8AC10A275779 Q35831031-BFE04F4E-5596-47FC-A7F2-4CCDCEA7F24A Q35870384-84697741-12DC-4501-9D13-9763A903A536 Q36089655-A79EED37-6ED2-42F0-AEE9-E2D23B0158BB

P2860

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

http://www.wikidata.org/entity/Q28168742

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Association of frequency and d ...... status with breast cancer risk

@ast

Association of frequency and d ...... status with breast cancer risk

@en

Association of frequency and d ...... status with breast cancer risk

@nl

type

label

Association of frequency and d ...... status with breast cancer risk

@ast

Association of frequency and d ...... status with breast cancer risk

@en

Association of frequency and d ...... status with breast cancer risk

@nl

prefLabel

Association of frequency and d ...... status with breast cancer risk

@ast

Association of frequency and d ...... status with breast cancer risk

@en

Association of frequency and d ...... status with breast cancer risk

@nl

P1433

Q28168742-5B55A641-900D-4369-8361-9B93D5859007

P1476

Q28168742-7FB08214-7F9A-4E89-AB70-876D01E8362D

P2093

Q28168742-201D4717-FC75-4206-95B4-2FFAA7A5A5C2

Q28168742-295E329D-6C05-4DFA-9C14-EE3CBAEA0321

Q28168742-49AA71B4-04EF-4A00-8703-23558181A804

Q28168742-692C58F2-BFC4-449E-B18F-57B28F450DB6

Q28168742-6FD7173C-93D1-485B-8E14-0B47E17E97AE

Q28168742-81C81A42-4592-4CDD-822B-E95C2EA2F17B

Q28168742-8EDA7744-8EC6-43F4-9BB9-AAEE5892697C

Q28168742-DEFCD316-DB78-4859-8C26-623CE0A6A26B

P304

Q28168742-07360725-BFED-4D4C-9D94-D02E5F6FD9FB

P31

Q28168742-190C1A88-7ED2-43BD-96A1-677D10A6A95F

P3181

Q28168742-A6018F85-B665-4A72-A910-33CBF65BB9C2

P356

Q28168742-70BB87CB-284E-4BFC-8459-8D54BB772181

P407

Q28168742-1A2B4407-D93B-4401-91C4-81796A075430

P433

Q28168742-7CA6D8D3-C262-441B-9405-CE9DFA1FCB1F

P478

Q28168742-215315B4-4E86-4834-B713-642B8720441F

P50

Q28168742-50DFBCDF-349F-455D-9CB5-F3D311A71E79

P577

Q28168742-DE9F84F6-9A38-4C84-863D-653ACC586E97

P5875

Q28168742-10E65236-1CBC-4866-AFC1-11A27147E294

P698

Q28168742-FDC0624F-0877-45BF-91C2-2401834AEF31

P921

Q28168742-C2DDA9DC-D703-4E99-AA38-E02CF0735EF6

P3181

P356

JAMA.291.20.2433

P1433

Journal of the American Medical Association

P1476

Association of frequency and d ...... status with breast cancer risk

@en

P2093

Alfred I Neugut

http://www.w3.org/2001/XMLSchema#string

Andrew J Dannenberg

http://www.w3.org/2001/XMLSchema#string

Fang Fang Zhang

http://www.w3.org/2001/XMLSchema#string

Heba Tawfik

http://www.w3.org/2001/XMLSchema#string

Julie A Britton

http://www.w3.org/2001/XMLSchema#string

Kotha Subbaramaiah

http://www.w3.org/2001/XMLSchema#string

Marilie D Gammon

http://www.w3.org/2001/XMLSchema#string

Susan L Teitelbaum

http://www.w3.org/2001/XMLSchema#string

P304

2433-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2601821

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.291.20.2433

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

291

http://www.w3.org/2001/XMLSchema#string

P50

Mary Beth Terry

P577

2004-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8544353

http://www.w3.org/2001/XMLSchema#string

P698

15161893

http://www.w3.org/2001/XMLSchema#string

P921